Dowling Paul, Shields William, Rani Sweta, Meleady Paula, Henry Michael, Jeppesen Per, O'Driscoll Lorraine, Clynes Martin
National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
Electrophoresis. 2008 Nov;29(20):4141-9. doi: 10.1002/elps.200800152.
Media conditioned by dysfunctioning pancreatic beta cells offer an excellent source of potential protein markers associated with this phenotype. Proteins identified from cell culture model systems are often found to be of importance clinically. Previous work by us and others have shown that low-passage MIN-6 cells (MIN-6(L)) respond to changes in glucose concentrations, producing an approximately 5.5-fold glucose-stimulated insulin secretion (GSIS) in response to 26.7 mmol/L, compared with 3.3 mmol/L, glucose. After continuous culture or high-passage (MIN-(H)), this GSIS was no longer present and thus represents an excellent model system for investigating beta cell dysfunction. Employing 2-D difference gel electrophoresis and mass spectrometry a panel of protein markers were identified in conditioned media (CM) from MIN-6(L) and MIN-6(H) beta cells. These proteins, including secretogranin II, secretogranin III and transthyretin, are associated with secretory granule biogenesis and were found to have substantially increased levels in the CM from the non-responsive high-passage MIN-6 beta cells. A panel of protein markers found to have increased abundance levels in CM from MIN-6(H) compared with MIN-6(L) beta cells may have the potential to be used clinically for assessing beta cell function and to monitor the effects of specific therapeutics.
由功能失调的胰腺β细胞所调节的培养基提供了与该表型相关的潜在蛋白质标志物的极佳来源。从细胞培养模型系统中鉴定出的蛋白质在临床上往往具有重要意义。我们和其他人之前的研究表明,低传代的MIN-6细胞(MIN-6(L))对葡萄糖浓度的变化有反应,与3.3 mmol/L葡萄糖相比,在26.7 mmol/L葡萄糖刺激下产生约5.5倍的葡萄糖刺激胰岛素分泌(GSIS)。连续培养或高传代(MIN-(H))后,这种GSIS不再存在,因此它是研究β细胞功能障碍的极佳模型系统。利用二维差异凝胶电泳和质谱技术,在MIN-6(L)和MIN-6(H)β细胞的条件培养基(CM)中鉴定出一组蛋白质标志物。这些蛋白质,包括分泌粒蛋白II、分泌粒蛋白III和甲状腺素运载蛋白,与分泌颗粒的生物发生有关,并且发现在无反应的高传代MIN-6β细胞的CM中水平大幅增加。与MIN-6(L)β细胞相比,在MIN-6(H)的CM中丰度水平增加的一组蛋白质标志物可能具有临床应用潜力,可用于评估β细胞功能并监测特定治疗方法的效果。